As expected the details are not entirely clear as yet. Initial order of US$1B for anti-virals with no breakdown. That is enough for about 30-40 million courses of either drug.
Neither can be supplied any time soon so assume 40% only is Relenza ie $32 M to BTA from about 15 million courses.
This would take most of the production run that will not be available before the middle of next year (if it hasn't already been sold to other stockpile inventories). Does not appear as the retail market will be supplied for a very long time unless they intend keeping a small amount in the market to satisfy/manipulate/manage demand from private buyers. People want more of what they can't have.
BTA Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
